A number of firms have modified their ratings and price targets on shares of Immunomedics (NASDAQ: IMMU) recently:
- 7/25/2017 - Immunomedics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
- 7/24/2017 - Immunomedics had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $15.00 price target on the stock.
- 7/17/2017 - Immunomedics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $10.00 price target on the stock. According to Zacks, “Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. “
- 7/14/2017 - Immunomedics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $11.00 price target on the stock.
- 7/12/2017 - Immunomedics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. “
- 7/11/2017 - Immunomedics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “buy” rating. They now have a $9.50 price target on the stock. According to Zacks, “Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. “
- 6/10/2017 - Immunomedics was given a new $9.00 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
- 6/2/2017 - Immunomedics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
Shares of Immunomedics, Inc. (IMMU) opened at 8.80 on Thursday. The company has a 50-day moving average of $8.49 and a 200-day moving average of $6.45. The stock’s market capitalization is $964.52 million. Immunomedics, Inc. has a 52 week low of $2.02 and a 52 week high of $9.51.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
